OUR
MEDICINES

EARLY PATIENT ACCESS TO
INVESTIGATIONAL MEDICINES

Consistent with Takeda-ism, we are committed to providing safe, fair and sustainable patient access to its products at different stages of lifecycle development.

In some cases, we may be able to provide patients access to its investigational drugs outside of a clinical trial if certain conditions are met and if permitted by local law and regulation. The use of investigational drugs outside of a clinical trial is known as Expanded Access. Expanded Access may not always be available and requires the individual patient meet certain eligibility conditions:

  • Diagnosed with a serious, life-threatening or severely debilitating disease;
  • Unable to participate in Takeda clinical trials; and
  • Have no comparable or satisfactory alternative treatment option available.

In addition, we will consider providing Expanded Access only if the risk/benefit profile of the investigational drug is favorable in light of the sufficient safety and efficacy information and the treating physician’s assessment of the patient’s medical condition.

Learn more about our Expanded Access programs

HOW TO REQUEST ACCESS TO
INVESTIGATIONAL MEDICINES

Licensed healthcare professionals in areas outside of the United States who are interested in the following Takeda investigational products may request further information using the below contact details.

Recently Added: Mobocertinib
Clinigen Group plc

Online Request: https://cliniport.co.uk/
Email: medicineaccess@clinigengroup.com

For requests to other Takeda investigational drugs, please email expandedaccess@takeda.com.

Recently Added: Pevonedistat
Online Request: www.YourPatientAccess.com
Email: Patient.Access@Bionical-Emas.com

Phone numbers:

  • France: +33 805 981 271 
  • Spain: +34 800 000 873
  • US: + 1 (888) 704-9397
  • Canada: +1 (888) 346-8672
  • Italy: + 39 800694277
  • Germany: +49 71211453726
  • UK: +44 1462354006

Brigatinib (ALUNBRIG®) 
Clinigen Group plc

Online Request: https://cliniport.co.uk/
Email: medicineaccess@clinigengroup.com


Tel: +44 1283 494 340
Fax: +44 1283 494 341


Tel: 065 250 307
Fax: +44 1283 494 341


Tel: 0800 903 406
Fax: 0805 109 994


Tel: 069 2222 3413
Fax: 0800 589 2457


Tel: 800 977 669
Fax: 800 977 686


Tel: 800 600 217
Fax: 800 600 218


Tel: +44 1283 494 340
Fax: +44 1283 494 341

Ixazomib (NINLARO®) 
Clinigen Group plc

Online Request: https://cliniport.co.uk/
Tel: +44 1283 494 340
Fax: +44 1283 494 341
Email: medicineaccess@clinigengroup.com

Brentuximab vedotin (ADCETRIS®)
Clinigen Group plc

Tel: +44 1932 824 123
Fax: +44 1932 824 323
Email: row@clinigengroup.com

Mifamurtide (MEPACT®)
Clinigen Group plc

Tel: +44 1932 824 123
Fax: +44 1932 824 323
Email: row@clinigengroup.com